Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1363 results for social care

  1. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued Reference number: GID-TA10186

  2. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

  3. Lifitegrast for treating dry eye disease [ID1229]

    Discontinued Reference number: GID-TA10196

  4. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

  5. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

  6. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

  7. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

  8. Structured clinical management interventions in probation service providers:- What is the effectiveness of structured clinical (case) management in improving mental health outcomes using interventions within probation service providers?

    both CRCs and the NPS. The comparison should be against standard CRC and NPS care. The trial should consider both clinical outcomes and...

  9. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  10. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

  11. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

  13. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued Reference number: GID-TA10199

  14. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  15. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    for vulnerable groups.In the committee's experience, professionals such as care workers and health visitors, and the public, are...